AzTrials
AzTrials

BMI/Body CompositionNCT04737681

Influence of Body Weight and Composition on Immune Recovery

An observational study of BMI/Body Composition, run by United States Army Research Institute of Environmental Medicine at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Immune dysfunction in individuals with obesity, secondary to chronic inflammation, may have an acute impact on War fighter health and readiness, and subsequent lethality. Indeed, ~51% of military personnel ages 17 or older are overweight, and ~15% have obesity (ranging from 6.4% in the Marine Corps to 18.0% in the… Read more about this study

Who is it for?
Ages 18 to 39 yearsHealthy volunteers can take part
Conditions the study is for
BMI/Body Composition
What is being tested?
body composition
How many people
50 participants
Where
1 siteUnited States
Study dates
1 Sep 2020to Sep 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 39 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: The participant population will consist of military personnel (male or female) and civilians. Participants will be matched for both sex and the proportion of participants above and below 30 years of age. Potential participants will be screened for body mass index (BMI), percent body fat and aerobic exercise habits.

Who may be able to join

  • Are between the ages of 18 (or 17 for military personnel) and 39 (i.e., consistent with the age range of 95% of Active Duty enlisted and 75% of Active Duty officers)
  • Have a Body Mass Index (BMI) in the range of 18.5 to <25 kg/m2 and have a percent body fat by circumference measurements that meets the Army's max allowable body fat standards for individuals classified as "without obesity"; or have a BMI ≥ 30 kg/m2 and have a percent body fat by circumference measurements that exceeds the Army's max allowable body fat standards for individuals classified as "with obesity" (40).
  • Have been weight stable (+/- 5 lbs.) for the past two months (not including temporary body weight fluctuations due to menstrual cycle) and agree not to attempt to lose or gain weight for the duration of the study;
  • Participate in 120-300 mins of aerobic exercise over the course of at least 3 days per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with the self-reported exercise habits of a majority of active duty military personnel) (1, 41)
  • Are willing to participate in all study procedures and comply with all study instruction.
  • Females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or able to provide documentation of oral/hormonal contraceptive use which contains low-dose estrogen/progesterone to maintain continuous levels throughout the 28-day cycle (i.e., no placebos)
  • Pass a general medical clearance.

Who cannot join

  • have a tattoo on both forearms that obscures the forearms and doesn't allow space for the suction blister induction;
  • experienced more than a ~5 lbs. weight gain or loss in the last month than is not transient (e.g., menstrual).
  • participate in more than 300 minutes of aerobic exercise per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with self-reported exercise habits of ~20% of active duty military personnel) (1, 41).
  • are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil), aspirin, lipid-lowering drugs, corticosteroids or immunosuppressants (e.g. Humira);
  • are immune-compromised (e.g., chemotherapy or radiation treatment);
  • are suffering from an autoimmune disease (e.g., lupus);
Show all 16Show fewer
  • recovering from a surgery within the past 6 months;
  • Current doctor-diagnosed and/or treated diabetes, hypertension or dyslipidemia
  • are suffering from sleep apnea;
  • smoke, dip, chew or vape tobacco or nicotine-containing products.
  • regularly (more than 2 days per week) sleep less than 7 hours or more than 9 hours per night; or, take a nap 3 or more days per week.
  • Pregnant or lactating
  • problems with blood clotting (in the subset of participants receiving muscle biopsies only)
  • allergy to lidocaine (in the subset of participants receiving biopsies only)
  • Females Only:
  • Have abnormal menstrual cycles (not between 26-32 days in duration; or not 5-6 menstrual cycles within the past 6 month) or those that have had an intrauterine device (IUD) placed with the last month or removed within the past 3 months.

Trial locations and contacts

1 site in 1 country.

Tracey J Smith, PhD, RD contact

508-206-2390

Tracey.smith10.civ@health.mil

United States1 site, 1 recruiting
  • U.S. Army Research Institute of Environmental Medicine

    Natick, Massachusetts, 01760

    Tracey J Smith, PhD, 508-233-4868, tracey.smith10.civ@health.mil

    Recruiting

Other trials in United States

About this study

Immune dysfunction in individuals with obesity, secondary to chronic inflammation, may have an acute impact on War fighter health and readiness, and subsequent lethality. Indeed, ~51% of military personnel ages 17 or older are overweight, and ~15% have obesity (ranging from 6.4% in the Marine Corps to 18.0% in the Army). In conjunction with in vitro functional tests to assess systemic immune function, the suction blister model is a minimally invasive procedure that allows in vivo assessment of immune function (i.e., skin barrier restoration), and related mechanisms (i.e., pro- and anti-inflammatory cytokine responses at the wound site during the early phases of wound healing), consequent to obesity. We have demonstrated that the blister wound model reliably assesses skin barrier restoration and immune function at the wound site; and that relatively modest sleep disruption degrades immune response at the site of the disrupted skin barrier and delays the initial restoration of the skin barrier. However, our prior work excluded participants with obesity (≥30 kg/m2), since obesity is associated with an altered inflammatory response which may subsequently impact the body's functional response to a skin wound. Prior studies have indicated that immune function and wound healing is perturbed in individuals with obesity versus those without obesity. Existing research mainly relied on blood biomarkers and in vitro tests to assess systemic immune function; however, incorporating the blister wound model permits evaluation of the functional immune response to obesity in addition to local immune response at the wound site. Further, military personnel with obesity may be more physically active than civilians with obesity, which could mitigate the effects of obesity on immune dysfunction. Therefore, the primary aim of this parallel-group study is to utilize a suction blister model and in vitro functional assays to examine differences in immune function between participants without obesity (BMI 18.5-24.9 kg/m2) and with obesity (BMI ≥ 30 kg/m2) and related mechanisms (e.g., local cytokine response at the wound site and circulating markers of inflammation). Research will be conducted in a laboratory environment using males and females with obesity (BMI ≥ 30 kg/m2) compared to normal weight (BMI 18.5-24.9 kg/m2) controls. Participants in the study described herein (n = 50; n = 25 with obesity and n = 25 lean) will undergo baseline testing and a period of dietary surveillance prior to induction of up to eight blisters via suction on participant's forearm, after which time the top layer of blisters will be removed to reveal the dermal layer of skin. The primary outcome measure is initial restoration of the skin barrier (via transepidermal water loss) and additional outcome measures include immune function (e.g., circulating markers of inflammation, cytokines at the blister site, and secretory immunoglobin) and nutrient status. Additionally, to assess the impact of BMI on skeletal muscle inflammation, a subset of volunteers (n = 12 with obesity and n =12 lean) will undergo a single muscle biopsy at the conclusion of skin barrier restoration. Findings from this study will determine if obesity affects the early phases of wound healing and whether further study is warranted, e.g., do stressors exacerbate immune decrements observed in obese individuals, or can nutrition counter-measures mitigate immune decrements given that micronutrient deficiency is common in individuals with obesity.

Read the detailed description

See brief summary above.

Being tested
body composition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • body compositionOther

    This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.

Study groups in NCT04737681
Study groupRoleWhat they receive
Normal BMIBMI 18.5-24.9 kg/m2
Receives: Other: body composition
Obese BMIBMI ≥ 30 kg/m2
Receives: Other: body composition

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Initial restoration of the skin barrier

    initial restoration of the skin barrier (via transepidermal water loss)

    Measured: 4-10 days

Secondary outcomes (3)
  1. circulation markers of inflammation

    Interleukin (IL) 6, IL8, tumor necrosis factor alpha, c-reactive protein

    Measured: baseline

  2. cytokines at the wound site

    Interleukin (IL) 6, IL8, IL10, tumor necrosis factor alpha

    Measured: 72 hours

  3. mucosal immune function

    mucosal immune function will be measured via salivary secretory immunoglobulin A

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2021
  2. Study start1 Sep 2020
  3. Primary completionDec 2023 (estimated)
  4. Study completionSep 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04737681
Sponsor's protocol ID
19-26HC
Status last verified
Oct 2022
First submitted
24 Aug 2020
Last updated
26 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of BMI/Body Composition, run by United States Army Research Institute of Environmental Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tracey J Smith, PhD, RD (508-206-2390, Tracey.smith10.civ@health.mil), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Initial restoration of the skin barrier (time frame: 4-10 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in